A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer

ClinicalTrials.gov ID: NCT07659795

Public ClinicalTrials.gov record NCT07659795. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 9:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, With and Without an Anti-EGFR Antibody, and With an Anti-EGFR Antibody and Chemotherapy, in Patients With Metastatic KRAS G12D-Mutated Colorectal Adenocarcinoma (TARGET-D 203)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab or panitumumab and cetuximab plus mFOLFOX in patients with metastatic KRAS G12D - mutated Colorectal Cancer

Study identification

NCT ID: NCT07659795
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Verastem, Inc.; Industry
Enrollment: 150 participants

Conditions and interventions

Conditions

Colorectal Cancer

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 27, 2026
Primary completion: May 31, 2027
Completion: Nov 30, 2028
Last update posted: Sep 1, 2026

2026 – 2028

United States locations

U.S. sites: 11
U.S. states: 10
U.S. cities: 10

Facility	City	State	ZIP	Site status
START Los Angeles	Los Angeles	California	90025	Recruiting
Valkyrie Clinical Trials (contact for more locations)	Los Angeles	California	90067	Recruiting
Moffitt Cancer Center	Tampa	Florida	33612	Recruiting
Indiana University, Simon Comprehensive Cancer Center	Indianapolis	Indiana	46202	Recruiting
START Midwest	Grand Rapids	Michigan	49546	Recruiting
START New Jersey	East Brunswick	New Jersey	08816	Recruiting
Sarah Cannon Research Institute Oncology Partners	Nashville	Tennessee	37203	Recruiting
START Dallas Fort Worth	Fort Worth	Texas	76104	Recruiting
START Mountain Region	West Valley City	Utah	84119	Recruiting
UVA Comprehensive Cancer Center	Charlottesville	Virginia	22908	Recruiting
Virginia Mason Medical Center	Seattle	Washington	98101	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07659795, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Sep 1, 2026 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07659795 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →